the aid library

The document covers: introduction on contact tracing in the Ebola response; general considerations for contact tracing; case definition; planning and preparation; personnel; implementation, and tools for contact tracing.

Download (65)

View PDF (89)

Ministerial policy dialogue on HIV and related comorbidities in eastern Europe and central Asia (EECA)

World Health Organization (Europe); Government of the Netherlands; UNAIDS (2019) C_WHO

Amsterdam, the Netherlands, 23 July 2018 Meeting Report

Download (70)

View PDF (114)

2014 Update - Elimination of Mother-to-Child Transmission of HIV and Syphilis in the Americas

M. Alonso González; A. Spaulding; M. Beusenberg et al. Pan American Health Organization; World Health Organization (Americas); Unicef (2014) C_WHO

Download (110)

View PDF (122)

Elimination of mother-to-child transmission of HIV and syphilis in the Americas

M. Alonso González; M. B. Mello.; A. Benzaken; et al. Pan American Health Organization; World Health Organization (Americas); Unicef; et al. (2017) C_WHO

Update 2016

Download (397)

View PDF (1828)

Strengthening community mental health resources by training refugees as peer counselors - A manual for trainers

Josi Salem-Pickartz Al Himaya Foundation for Trauma Recovery, Growth and Resilience (2008)

Download (482)

View PDF (578)

Nambia: National Guidelines on post-Exposure Prophylaxis for HIV, HBV and Tetanus

Ministry of Health and Social Services (MOHSS) (2010) C2

After Workplace exposures and Sexual Assault | DIRECTORATE: PRIMARY HEALTH CARE SERVICES | DIVISION: PUBLIC AND ENVIRONMENTAL HEALTH | SUB-DIVISION: OCCUPATIONAL HEALTH SERVICES

Download (546)

View PDF (1853)

Living conditions among people with disabilities in Southern Africa

SAF OD, FFO and SINTEF (2017)

Accessed November 2, 2017

Download (67)

View PDF (97)

Defining Disability - A Guideline for Medical Doctors and Primary Health Care Workforce

Prof. AHM E. Hussain; Dr. N. Mohammad; Dr. Md. R. Karim; et al. Government of the People's Republic of Bangladesh DGHS Directorate General of Health Services Ministry of Health and Family Welfare ; NCDC; drra; et al. (2019) C2

January 2019 Non Communicable Disease Control Programme Directorate General of Health Services Health Services Division, Ministry of Health & Family Welfare

Download (163)

View PDF (208)

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

World Health Organization WHO (2022) C_WHO

This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi... more

Download (59)

View PDF (93)

COVID-19 infection prevention and control living guideline: mask use in community settings, 22 December 2021

World Health Organization WHO (2021) C_WHO

22 December 2021

Download (91)

View PDF (144)

What are patient navigators and how can they improve integration of care?

Budde, H.; G.A.Williams, G. Scarpetti, et al. World Health Organization WHO, Regional Office of Europe (2021) C_WHO

Policy brief

Download (117)

View PDF (185)

Vienna Declaration: building forward better by transforming to new, clean, safe, healthy and inclusive mobility and transport

World Health Organization (WHO) (2022) C_WHO

The Vienna Declaration was signed at the end of the Fifth High-level Meeting on Transport, Health and Environment. The virtual meeting, hosted by the Federal Government of Austria, brought together 46 ministers and representatives of 56 countries in the pan-European region. The group discussed ho... more

Download (77)

View PDF (118)

WHO Meeting on Buruli ulcer and other skin NTDs. Final report.

World Health Organization WHO (2019) C_WHO

The World Health Organization (WHO) convened a meeting of the Technical Advisory Group on Buruli ulcer at its headquarters in Geneva, Switzerland on 25 to 27 March 2019

Download (82)

View PDF (112)

African Regional Convening to Support Parents and Caregivers

World Health Organisation (WHO) (2023) C_WHO

The African Regional Convening of the Global Initiative to Support Parents (GISP) stimulated the interest or engagement of almost 1500 individuals from 742 unique organizations in the fields of health, education, social welfare, women’s affairs, early childhood, water and sanitation, mental health... more

Download (68)

View PDF (93)

Morbidity management and disability prevention in lymphatic filariasis

World Health Organization (WHO) (2013) C_WHO

The content of these guidelines goes beyond the technicalities of medical needs with additional insights into community empowerment, possible access to welfare and economic opportunities and similar issues. If these are adequately explored, the health and quality of life of people affected and their... more

Download (181)

View PDF (152)

Infection prevention and control guideline for Ebola and Marburg disease, August 2023
recommended

World Health Organization WHO (2023) CC

Ebola disease and Marburg disease outbreaks continue to occur in Africa, with increased frequency. In addition to resulting in high mortality and morbidity, the outbreaks generate fear and mistrust about the response activities within the communities affected. Infection prevention and control (IP... more

Download (176)

View PDF (247)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Therapeutics and COVID-19: living guideline, Updated 16 September 2022 recommended

Infection prevention and control guideline for Ebola and Marburg disease, August 2023 recommended

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

Infection prevention and control guideline for Ebola and Marburg disease, August 2023
recommended